Navigation Links
Updated: LHA Life Sciences & Medical Technologies Virtual Conference
Date:6/27/2012

NEW YORK, June 27, 2012 /PRNewswire/ --

Thursday, June 28, 2012The event will feature 30-minute corporate presentations with accompanying slides by executives from seven industry leaders.Presentations begin at 9:00 a.m. Eastern Time and can be accessed at www.informedinvestors.com.  Individual presentations also will be available at each presenting company's website.We hope you can join us.If you cannot attend the live event, presentations will be archived at www.informedinvestors.com and at each presenting company's website for approximately 90 days.  If you have any questions, please call Carolyn Curran at (212) 838-3777 or ccurran@lhai.com.Time (Eastern Time)CompanyTicker SymbolWebsite9:00 a.m.CAS Medical Systems, Inc.Nasdaq: CASMwww.casmed.com9:30 a.m.Chembio Diagnostics, Inc.NasdaqCM: CEMIwww.chembio.com10:00 a.m.Derma Sciences, Inc.NasdaqCM: DSCIwww.dermasciences.com10:30 a.m.PhotoMedex, Inc.NasdaqGM: PHMDwww.photomedex.com11:30 a.m.Spherix, Inc.NasdaqCM: SPEXwww.spherix.com12:00 p.m.Tonix Pharmaceuticals.OTCBB: TNXPwww.tonixpharma.com12:30 p.m.NovelosTherapeuticsOTCBB: NVLTwww.novelos.comLHA is a leading independent investor relations firm. As IR specialists with more than 25 years of experience, we partner with public and soon-to-be public companies to create and support best practices investor and media relations programs. By focusing on the development of public company identity and the communication of strategic vision, we build awareness, enthusiasm and sponsorship among target audiences in the investment community to maximize valuation.  Our programs deliver measurable results so clients can assess the impact of their investor relations initiatives.

LHA Life Sciences & Medical Technologies Virtual Conference 
June 28, 2012 beginning at 9:00 a.m. Eastern Time 

9:00 a.m. Eastern Time
CAS Medical Systems is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT® Absolute Cerebral Oximeter is the only cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for all patients, regardless of age or weight.   Direct monitoring of tissue oxygenation provides a unique and powerful tool to alert clinicians to otherwise unrecognized and dangerously low levels of oxygenation of the brain and other tissues, thereby allowing them to intervene appropriately in the care of their patients. In addition to FORE-SIGHT Oximeters and accessories, the Company provides a line of bedside patient vital signs monitoring products, proprietary non-invasive blood pressure monitoring solutions for OEM use, neonatal intensive care supplies, and service. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates. For additional information please visit www.casmed.com

9:30 a.m. Eastern Time
Chembio Diagnostics develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $10 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical Innovations, Inc.). Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors.  Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies.  This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP®. Headquartered in Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U. S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485.  For additional information please visit www.chembio.com.

10:00 a.m. Eastern Time
Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings.  Derma Sciences has successfully completed the Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, an investigational pharmaceutical drug under development for accelerated wound healing and scar reduction, and is preparing to begin Phase 3 clinical trials.  Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns.  The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers.  Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, BIOGUARD® for infection prevention and TCC-EZ™, a gold-standard treatment for diabetic foot ulcers. For additional information please visit www.dermasciences.com.

12:30 p.m. Eastern Time
Novelos is a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer.  The Company's three cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells.  Thus, Novelos' therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells.  This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse.  I-124-CLR1404 (LIGHT) is a small-molecule cancer-targeted PET imaging agent which the Company believes has first-in-class potential and for which Phase 1-2 clinical trials are ongoing.  I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells.  The Company believes HOT also has first-in-class potential.  HOT Phase 1b dose-escalation trial is ongoing and is expected to enter Phase 2 trials in the first quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need, subject to additional funding.  CLR1404 (COLD), a pre-clinical cancer-targeted non-radioactive chemotherapy, works primarily through Akt inhibition.  Together, Novelos believes its compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way.  For additional information please visit www.novelos.com

10:30 a.m. Eastern Time
PhotoMedex is a global skin health company providing integrated disease management and aesthetic solutions to dermatologists, professional aestheticians and consumers. The company provides proprietary products and services that address skin diseases and conditions including psoriasis, vitiligo, acne, actinic keratosis (a precursor to certain types of skin cancer) and photo damage. Its experience in the physician market provides the platform to expand its skin health solutions to spa markets, as well as traditional retail, online and infomercial outlets for home-use products. As a result of its December 2011 merger with Radiancy Inc., PhotoMedex has added a range of home-use devices under the no!no!™ brand, for various indications including hair removal, acne treatment and skin rejuvenation. The company also offers a professional product line for acne clearance, skin tightening, psoriasis care and hair removal sold to physician clinics and spas. For additional information please visit www.photomedex.com

11:30 a.m. Eastern Time
Spherix was launched in 1967 as a scientific research company under the name Biospherics Research.  The Company now leverages its scientific and technical expertise and experience through its two subsidiaries – Biospherics Incorporated and Spherix Consulting, Inc.  Biospherics is dedicated to developing and licensing/marketing proprietary therapeutic products for treatment of diabetes, metabolic syndrome and atherosclerosis.  Biospherics is actively seeking a pharmaceutical partner to continue the development of its Phase 3 compound for the treatment of diabetes, D-tagatose, while exploring new drugs and combinations for treatment of high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke.  Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides.  For additional information please visit www.spherix.com

12:00 p.m. Eastern Time
Tonix is developing innovative prescription medications for challenging disorders of the central nervous system. The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX's core technology improves the quality of sleep in patients with chronic pain syndromes. TONIX's lead products are designed to be fundamental advances in sleep hygiene and pain management and to be safer and more effective than currently available treatments. TONIX's products are the result of a program to harvest advances in science and medicine to search for potential therapeutic solutions among known pharmaceutical agents. TONIX is developing new formulations that have been optimized for new therapeutic uses. Its most advanced product candidates, TNX-102 for FM and TNX-105 for PTSD, are novel dosage formulations of cyclobenzaprine, the active ingredient in two U.S. FDA-approved muscle relaxants. For additional information please visit www.tonixpharma.com.


'/>"/>
SOURCE LHA
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. LHA Life Sciences & Medical Technologies Virtual Conference
2. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
3. Spot On Sciences Awarded $1 Million DARPA Grant to Develop a Blood Sample Collection Device
4. Indiana leads U.S. in life sciences jobs and growth
5. Oriel STAT A MATRIX Welcomes New Global Practice Head for Medical Devices and Life Sciences
6. Particle Sciences Expands its cGMP Capabilities with the Addition of Thin Films
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. USANA Health Sciences Expands Award-Winning Research and Development Team
9. BIOCRATES Life Sciences to Launch Waters Xevo® TQ MS Editions for Two of its Well-established Research Kit Products, AbsoluteIDQ® p180 and p150
10. Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences
11. Egalet to Present at Life Sciences Europe Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 10, 2016  Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ... reverse split of its issued and outstanding shares of ... Thursday, February 11, 2016. The Company,s common stock will ... 76303T308 and temporary ticker symbol "RCHAD". After 20 trading ... ticker symbol (RCHA).  --> ...
(Date:2/10/2016)... 2016  Oxis International Inc. (OTC/QB: OXIS) announced today ... as a "clinical trial triumph" after one of the ... cancer remission. Daniel Vallera , a ... Center. --> Daniel Vallera , a ... Center. --> An article on the ...
(Date:2/10/2016)... Feb. 10, 2016  The ALS Association, in partnership with ... Challenge to generate a biomarker to track TDP43 aggregation. The ... to a $1 million investment. --> ... that affects nerve cells in the brain and the spinal ... and control muscle movement, which often leads to total paralysis ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 10, 2016 , ... Early this week, Team Iconic at J. Walter Thompson ... as the first global confectionery brand sourced from 100% sustainable cocoa. , The Nestlé ... their product, through activities that focus on better farming, better lives and better cocoa. ...
(Date:2/10/2016)... ... ... As part of its ongoing series of aquatic therapy related webinars, HydroWorx ... dynamic expert and thoughtful presentation to give attendees a better sense of how to ... free to attend, but registration is required. , Rehabilitation of Offensive Lineman ...
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency ... find. Unfortunately, this can leave patients with dental emergencies at risk of losing a ... offering emergency dental care. , Common dental emergencies include:, , ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... will bring together more than 200 of the country’s top healthcare executives to ... , “The true benefit of the Forum is the provider-centric perspective, experience, expertise ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: ... winner and inspirational speaker Jan Fox will serve as keynote speaker at the ... provide participants with tools to more effectively communicate with their own organizational staff ...
Breaking Medicine News(10 mins):